Karen Leander

4.5k citations

32 papers · 3.4k indexed · 1 hit paper · h-index 20

Impact in

Immunology top 2%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Virology top 2%

Papers in

Gender Studies 4
- Sexual Assault and Victimization Studies 3
Health 3
- Intimate Partner and Family Violence 3

Co-authors: Arthur Friedman John Donnelly Jeffrey B. Ulmer John W. Shiver Douglas Martinez Helen C. Perry Margaret A. Liu Donna L. Montgomery
Journals: Molecular Carcinogenesis (2 papers)Bioorganic & Medicinal Chemistry Letters (2 papers)Carcinogenesis (2 papers)Bioconjugate Chemistry (2 papers)Nature Medicine (1 paper)
Partner nations: United States Sweden Belgium

In The Last Decade

Karen Leander

31 papers receiving 3.3k citations

Hit Papers

align trajectories log scale

Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein 1993 · 1.9k citations

Peers

Countries citing papers authored by Karen Leander

Since Specialization

Citations

This map shows the geographic impact of Karen Leander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Leander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Leander more than expected).

Fields of papers citing papers by Karen Leander

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen Leander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Leander. The network helps show where Karen Leander may publish in the future.

Co-authors

The 25 scholars most cited alongside Karen Leander, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Karen Leander Line = papers co-authored together Karen Leander links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials RMD Open ·Kristen Sweet, Qingxuan Song, Matthew J. Loza, Iain B. McInnes, Keying Ma, Karen Leander, Vani Lakshminarayanan, Mellysa Kowara, Philip Cooper, Stefan Siebert	2021	32
2	OP0229 GUSELKUMAB INDUCES SUSTAINED REDUCTION IN ACUTE PHASE PROTEINS AND TH17 EFFECTOR CYTOKINES IN ACTIVE PSORIATIC ARTHRITIS IN TWO PHASE-3 CLINICAL TRIALS (DISCOVER-1 AND DISCOVER-2) Annals of the Rheumatic Diseases ·Stefan Siebert, Iain B. McInnes, Matthew J. Loza, Ketao Ma, Karen Leander, Vani Lakshminarayanan, Mellysa Kowara, Philip Cooper, Kristen Sweet	2020	1
3	Characterization of a Novel Bispecific Antibody That Activates T Cells In Vitro and Slows Tumor Growth In Vivo Monoclonal Antibodies in Immunodiagnosis and Immunotherapy ·Olesya Chornoguz, Azza, Karen Leander, Danielle Nolin, Eva Emmell, Mark L. Chiu, Sandra Santulli-Marotto	2019	3
4	TIM-3 Engagement Promotes Effector Memory T Cell Differentiation of Human Antigen-Specific CD8 T Cells by Activating mTORC1 The Journal of Immunology ·知平谷口, Olesya Chornoguz, Karen Leander, Fred M. Kaplan, Richard Carter, Michelle Kinder, Kurtis E. Bachman, Raluca Verona, سارا شهبازی, Vipul Bhargava, Sandra Santulli-Marotto	2017	30
5	An in vivo evaluation of amphiphilic, biodegradable peptide copolymers as siRNA delivery agents International Journal of Pharmaceutics ·Stephanie E. Barrett, Marc Abrams, Rob S. Burke, Brian Carr, Louis S. Crocker, R. M. Garbaccio, Bonnie J. Howell, Jia Zhao, W.L. Wong, Andrew H. Latham, Karen Leander, Anthony Leone, Mihir Patel, Sergei Pechenov, Nicole T. Pudvah, Tian-Liang Liu, Laura Sepp‐Lorenzino, Eileen S. Walsh, Jonathan Williams, Steven L. Colletti	2014	13
6	An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo Cancer Biology & Therapy ·E Gatti, Kathleen Haskell, Bonnie J. Howell, Raymond C. F. Jones, Karen Leander, R. Robinson, Sanika M Thakur, Mark T. Bilodeau, J. M. HOFFMAN, Philip E.J. Sanderson, George D. Hartman, 雅俊柳沢, Thomayant Prueksaritanont, Guoqiang Jiang, Qing‐Bai She, Neal Rosen, Laura Sepp‐Lorenzino, Deborah Defeo-Jones, Hans E. Huber	2010	53
7	Androgen ablation augments human HLA2.1‐restricted T cell responses to PSA self‐antigen in transgenic mice The Prostate ·Mohamed S. Arredouani, Stephanie Tseng-Rogenski, Brent K. Hollenbeck, June Escara‐Wilke, Karen Leander, Deborah Defeo-Jones, Clara Hwang, Martin G. Sanda	2010	22
8	Abstract #3714: In vitro and in vivo antitumor activities of MK-2206, a new allosteric Akt inhibitor Cancer Research ·Wei Lu, Nan-Kuang Yi, Lenora J. Davis, Gaozhen Hang, Jennifer Tammam, Harold Hatch, Bart Lutterbach, Christopher Ware, Kathleen Haskell, Patrick Joseph Pardo, Karen Leander, E Gatti, Sanika M Thakur, Kelly Hamilton, Philip E.J. Sanderson, Hans E. Huber, Pradip K. Majumder, Bo‐Sheng Pan	2009	11
9	Allosteric inhibitors of Akt1 and Akt2: A naphthyridinone with efficacy in an A2780 tumor xenograft model Bioorganic & Medicinal Chemistry Letters ·Mark T. Bilodeau, Fatou Niasse Dia, J. M. HOFFMAN, Peter J. Manley, Stanley F. Barnett, Deborah Defeo-Jones, Kathleen Haskell, Raymond E. Jones, Karen Leander, R. Robinson, Anthony M. Smith, Hans E. Huber, George D. Hartman	2008	56
10	Allosteric inhibitors of Akt1 and Akt2: Discovery of [1,2,4]triazolo[3,4-f][1,6]naphthyridines with potent and balanced activity Bioorganic & Medicinal Chemistry Letters ·Yiwei Li, Jun Liang, Tony Siu, Essa Hu, Michael Rossi, Stanley F. Barnett, Deborah Defeo-Jones, Raymond E. Jones, R. Robinson, Karen Leander, Hans E. Huber, Sachin Mittal, Nicholas D. P. Cosford, Peppi Prasit	2008	49
11	Reflections on Sweden's Measures against Men's Violence against Women Social Policy and Society ·Karen Leander	2006	12
12	Preventing men's violence against women Acta Psychiatrica Scandinavica ·Karen Leander	2002	7
13	A peptide–doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo Nature Medicine ·Deborah Defeo-Jones, Victor M. Garsky, Bradley K. Wong, Dong-Mei Feng, Proy Vega B, Kathleen Haskell, DAVID M. KIEFER, Karen Leander, Elizabeth McAvoy, Patricia K. Lumma, Jenny Wai, Hui-Min Lu, Sherri L. Motzel, Kevin J Keenan, D. M. JONES, Jiunn H. Lin, Roger Freidinger, Joel R. Huff, Allen Oliff, Raymond E. Jones	2000	127
14	Induction of minisatellite DNA rearrrangements by genotoxic carcinogens in mouse liver tumors Carcinogenesis ·Brian J. Ledwith, 金順槇, Philip J. Troilo, Karen Leander, James H. Clair, Keith A. Soper, Sujata Manam, S. Prahalada, Matthew J. van Zwieten, Warren W. Nichols	1995	21
15	Dose-related changes in the profile of ras mutations in chemically induced CD-1 mouse liver tumors Carcinogenesis ·Sujata Manam, Gayle A. Shinder, 金順槇, Andrew R. Kraynak, علی جاویدان, Karen Leander, Brian J. Ledwith, S. Prahalada, Matthew J. van Zwieten, Warren W. Nichols	1995	15
16	Heterologous and Homologous Protection Against Influenza A by DNA Vaccination: Optimization of DNA Vectors DNA and Cell Biology ·Donna L. Montgomery, John W. Shiver, Karen Leander, Helen C. Perry, Arthur Friedman, Douglas Martinez, Jeffrey B. Ulmer, John Donnelly, Margaret A. Liu	1993	222
17	Activation of the Ki‐ras gene in spontaneous and chemically induced lung tumors in CD‐1 mice Molecular Carcinogenesis ·Sujata Manam, Richard D. Storer, S. Prahalada, Karen Leander, Andrew R. Kraynak, علی جاویدان, 金順槇, Brian J. Ledwith, Matthew J. van Zwieten, Matthews O. Bradley, Warren W. Nichols	1992	20
18	Murine p53 intron sequences 5–8 and their use in polymerase chain reaction/direct sequencing analysis of p53 mutations in CD‐1 mouse liver and lung tumors Molecular Carcinogenesis ·Tamra Goodrow, Richard D. Storer, Karen Leander, S. Prahalada, Matthew J. van Zwieten, Matthews O. Bradley	1992	69
19	A Mucin Containing the X, Y, and H Type 2 Carbohydrate Determinants Is Shed by Carcinoma Cells Hybridoma ·Ulrich Rodeck, Meenhard Herlyn, Karen Leander, ЗЕЛЕНСКАЯ АНАСТАСИЯ АЛЕКСАНДРОВНА, Hilary Koprowski	1987	14
20	Analysis of protein A encoded by a mutated gene of Staphylococcus aureus Cowan I European Journal of Biochemistry ·Bengt Guss, Karen Leander, Ulf Hellman, Mathias Uhlén, John Sjöquist, Martin Lindberg	1985	8

About Karen Leander

Karen Leander is a scholar working on Gender Studies, Health, Cancer Research, Immunology and Molecular Biology, having authored 32 papers that have together received 3.4k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (6 papers), RNA Interference and Gene Delivery (5 papers), Quinazolinone synthesis and applications (4 papers), Advanced biosensing and bioanalysis techniques (4 papers), Cancer-related Molecular Pathways (4 papers), Sexual Assault and Victimization Studies (3 papers), Immunotherapy and Immune Responses (3 papers) and Intimate Partner and Family Violence (3 papers). The work is most often cited by research in Immunology (1.4k citations), Virology (245 citations), Infectious Diseases (516 citations), Molecular Biology (1.7k citations) and Epidemiology (814 citations). Karen Leander has collaborated with scholars based in United States, Sweden and Belgium. Frequent co-authors include Arthur Friedman, John Donnelly, Jeffrey B. Ulmer, John W. Shiver, Douglas Martinez, Helen C. Perry, Margaret A. Liu, Donna L. Montgomery, Philip L. Felgner and Gary Rhodes. Their work appears in journals such as Molecular Carcinogenesis, Bioorganic & Medicinal Chemistry Letters, Carcinogenesis, Bioconjugate Chemistry and Nature Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact